Back to Journals » OncoTargets and Therapy » Volume 9

Values of 99mTc-methoxyisobutylisonitrile imaging after first-time large-dose 131I therapy in treating differentiated thyroid cancer

Authors Pan X, Duan D, Zhu Y, Pang H, Guan L, Lv Z

Received 8 August 2015

Accepted for publication 11 November 2015

Published 10 February 2016 Volume 2016:9 Pages 723—730

DOI https://doi.org/10.2147/OTT.S94036

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 3

Editor who approved publication: Professor Daniele Santini


Xiaomei Pan, Dong Duan, Yuquan Zhu, Hua Pang, Lili Guan, Zhixiang Lv

Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

Objective: The aim of this study is to investigate the use of 99mTc-methoxyisobutylisonitrile (MIBI) imaging for evaluating the treatment response of differentiated thyroid cancer (DTC) after the first administration of a high dose of 131I.
Methods: Patients with DTC who received 131I therapy underwent 99mTc-MIBI imaging after successive increases in the therapeutic dose of 131I, and the serum levels of thyroglobulin (Tg) were measured.
Results: A total of 191 patients were enrolled in the final analysis, including 65 metastases and/or thyroid remnant-positive patients (22 patients with metastases and 43 patients with thyroid remnants). The sensitivity of 99mTc-MIBI imaging for detecting positive cases and thyroid remnants was 56.9% and 39.5%, respectively, which was significantly lower than that of 131I imaging (92.3% and 100%, respectively, P<0.01 for both). The sensitivity of 99mTc-MIBI imaging for detecting metastases was 90.9%, which was slightly higher than that of 131I imaging (77.3%, P>0.05). The Tg levels in the positive group were significantly higher than that in the negative group (P<0.01). In addition, the Tg levels in the 99mTc-MIBI+/131I- group were significantly higher than that in the 131I+/99mTc-MIBI group (P<0.05).
Conclusion: After the first 131I therapy, although 99mTc-MIBI imaging was able to detect the existence of metastatic lesions in patients with DTC better, its assessment for the removal efficiency of thyroid remnants was unsatisfactory. The results of 99mTc-MIBI imaging showed good correlations with the Tg level.

Keywords:
differentiated thyroid cancer, 99mTc-MIBI imaging, therapeutic dose 131I imaging, thyroglobulin
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]